DR. DAVID J BERG, D.O.
Radiology at 27 Ave, Phoenix, AZ

License number

Arizona 1529

Personal information

See more information about DAVID J BERG at radaris.com

Name

Address

Phone

David Berg

5065 W Smoki Dr, Prescott, AZ 86305

(928) 443-5698

David Berg, age 65

4963 S Marigold Way, Chandler, AZ 85248

(928) 205-7071

David Berg

597 S Vermilion Cliffs Ave, Tucson, AZ 85748

(520) 298-0767

David Berg, age 64

5721 W Hearn Rd, Glendale, AZ 85306

David Berg, age 72

5553 W Pinnacle Hill Dr, Glendale, AZ 85310

(623) 516-0878

Professional information

Ceo Arrowhead Health Centers

Position:

Owner/CEO at Arrowhead Health Centers

Location:

Phoenix, Arizona Area

Industry:

Hospital & Health Care

Work:

Arrowhead Health Centers since Feb 1997 - Owner/CEO Accident Injury Management Clinic 1992 - 1995 - Clinical Coordinator

Education:

Canadian Memorial Chiropractic College 1987 - 1990
D.C., Chiropractic University of Toronto - University College 1983 - 1990
Hon. B.Sc., D.C., Biophysics, Biology, Chiropractic medicine Streetsville Secondary school 1978 - 1983

Skills:

Microsoft Office, Start-ups, Strategic Planning, Non-profits, Mergers

Interests:

The business of healthcare, golf, skiing, running, reading, hiking

Honor & Awards:

NCQA Certification as a Patient Centered Medical Home (Level 3)

David J Berg, Phoenix AZ

Specialties:

Radiologist

Address:

19829 N 27Th Ave, Phoenix, AZ 85027
10835 N 25Th Ave, Phoenix, AZ 85029

Education:

Midwestern University Chicago, College of Osteopathic Medicine - Doctor of Osteopathy
Emory University Hospital - Fellowship - Neuroradiology
Emory University Hospital - Residency - Radiology
George Washington University Hospital, The - Residency - Internal Medicine

Board certifications:

American Board of Radiology Certification in Diagnostic Radiology (Radiology)

Radiologist At Mdig, Ltd

Position:

Radiologist at MDIG, Ltd

Location:

Phoenix, Arizona Area

Industry:

Medical Practice

Work:

MDIG, Ltd - Radiologist

Method For Detecting, Treating, And Monitoring Conditions Associated With Activation Of The Coagulation Response

US Patent:

6692969, Feb 17, 2004

Filed:

Aug 11, 2000

Appl. No.:

09/637808

Inventors:

David E. Berg - Phoenix AZ 85022
Lois Hill Berg - Phoenix AZ 85022
Harold H. Harrison - Glen Rock NJ 07452

International Classification:

G01N 3386

US Classification:

436 69

Abstract:

This invention relates to a method for using a novel combination of assays to detect minimal activation of the coagulation response for determining whether a patient whose initial clinical evaluation indicates chronic fatigue syndrome, fibromyalgia, and related conditions can be treated using anticoagulant therapies. If activation of the coagulation response is detected, the present invention further includes treatment of CFS, FM or related condition using anticoagulant therapies.

Method For Detecting Procoagulant Genetic And Metabolic Conditions Associated With, And Potentially Predispositional For, Activation Of The Coagulation Response

US Patent:

7264936, Sep 4, 2007

Filed:

Aug 10, 2004

Appl. No.:

10/915018

Inventors:

David E. Berg - Phoenix AZ, US
Lois Hill Berg - Phoenix AZ, US
Harold H. Harrison - Scottsdale AZ, US

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin, plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.

Method For Detecting, Treating, And Monitoring Conditions Associated With Activation Of The Coagulation Response

US Patent:

2004016, Aug 19, 2004

Filed:

Oct 27, 2003

Appl. No.:

10/694033

Inventors:

David Berg - Phoenix AZ, US
Lois Berg - Phoenix AZ, US
Harold Harrison - Glen Rock NJ, US

International Classification:

C12Q001/56

US Classification:

435/013000

Abstract:

Disclosed is a method that includes steps of identifying conditions each associated with a low level activation of the coagulation response; conducting a clinical evaluation of a patient to determine a possibility that the patient has one of the conditions; if the clinical evaluation indicates the possibility that the patient has one of the conditions, providing a panel of different quantitative blood tests each capable of providing one of an abnormal result indicative of a low level activation of the coagulation response, and a normal result; performing the panel of different quantitative blood tests on the patient; obtaining a result for each of the blood tests; observing the results; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the patient with the one of the conditions.

Method For Detecting Procoagulant Genetic And Metabolic Conditions Associated With, And Potentially Predispositional For, Activation Of The Coagulation Response

US Patent:

2002003, Mar 28, 2002

Filed:

Sep 28, 2001

Appl. No.:

09/966311

Inventors:

David Berg - Phoenix AZ, US
Lois Berg - Phoenix AZ, US
Harold Harrison - Scottsdale AZ, US

International Classification:

C12Q001/68, G01N033/567, C12Q001/56

US Classification:

435/006000, 435/007210, 435/013000

Abstract:

Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.